For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 22,279 | 22,680 | ||
| General and administrative | 7,707 | 6,816 | ||
| Total operating expenses | 29,986 | 29,496 | ||
| Loss from operations | -29,986 | -29,496 | ||
| Interest income | 3,061 | 2,764 | ||
| Total other income, net | 3,061 | 2,764 | ||
| Net loss | -26,925 | -26,732 | ||
| Change in unrealized gains (losses) on investments, net of tax | 221 | 19 | ||
| Total other comprehensive income (loss) | 221 | 19 | ||
| Comprehensive loss | -26,704 | -26,713 | ||
| Basic EPS | -0.71 | -0.75 | ||
| Diluted EPS | -0.71 | -0.75 | ||
| Basic Average Shares | 37,931,170 | 35,444,635 | ||
| Diluted Average Shares | 37,931,170 | 35,444,635 | ||
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)